A 5-agonist is a single peptide designed to activate five metabolic receptors at the same time. TARGETS GLP-1 GIP Glucagon Amylin Calcitonin WHAT EACH ONE DOES GLP-1 Reduces appetite and slows digestion GIP Improves insulin response and nutrient handling Glucagon Increases calorie burn and energy output Amylin Enhances fullness and reduces meal size Calcitonin Extends satiety and supports metabolic regulation OVERALL EFFECT Lower food intake Longer-lasting fullness Higher energy expenditure Better glucose control WHAT IT IS A next-generation multi-agonist peptide built to combine appetite control, satiety, and calorie burning into one compound CURRENT STATUS Still in development and not commercially available SIMPLE SUMMARY One peptide Five pathways Full metabolic control in a single mechanism

It's only fair I address the situation head-on. As of now, I've found no direct evidence of Ion products coming up short in testing. There was what I was told a mishap with COAs being published while the product was never released. Ion was a strong company when I took them on in the beginning. If nothing else, they've become passive, and I do not recommend products that they may carry that will not be effective, such as shampoos amd strip things of that nature. I will do my due diligence and investigate the company; that's my job. And I will inform you guys as I find out new information.

We've made a decision that the last 2 peptira kit giveaways will be skool exclusive . This increases your chances dramatically to win!

Brenipatide is a new incretin-based peptide in development by Eli Lilly and Company. It works on the same general pathways as tirzepatide and retatrutide, targeting GIP and GLP-1 receptors. That part isn’t exciting. What’s different is what they’re trying to use it for. This isn’t just being looked at for fat loss or blood sugar. It’s being studied for things like alcohol cravings, smoking relapse, and even opioid-related behavior. That should tell you right away this isn’t just about eating less. This is about how the brain handles reward. Most people think GLP-1 equals appetite suppression. That’s surface level. The deeper layer is that these pathways interact with dopamine and reward signaling. That’s why some people on these compounds lose interest in food, alcohol, even certain habits. Brenipatide is being pushed further into that lane. So instead of thinking “this helps you eat less,” think “this might help you want less.” That’s a completely different conversation. Now here’s the reality. This is still in research. No real protocols, no long-term outcome data, and no clear idea yet where it will land compared to something like tirzepatide or retatrutide. So this isn’t something you should be chasing. But it is something to watch. Because if it does what they’re hoping, this class of peptides stops being just about fat loss and starts becoming about controlling cravings, habits, and behaviors at a much deeper level. That’s where things get interesting.

How many have heard of this... gonna do a break down and look ahead on this one today.